micTruely Your Radio

International

AstraZeneca CEO hails NHS drug price deal but keeps pause on £200m UK investment

todayFebruary 10, 2026

Background
share close

Pascal Soriot suggests UK-US agreement will not be enough to revive plan to expand Cambridge site

The boss of Britain’s biggest pharmaceutical company has said the government’s recent drug pricing deal is a “very positive step” but is unlikely to unfreeze a paused £200m investment in Cambridge.

AstraZeneca’s chief executive, Pascal Soriot, suggested that a UK-US deal on NHS pricing agreed in December would not be “sufficient” to restart the project to build a research site in the east of England, which was paused in September.

Continue reading…

Source: www.theguardian.com

Read full article

Written by: truelightfm

Rate it

Similar posts

Post comments (0)

Leave a reply

Your email address will not be published. Required fields are marked *